Home › Opioid Overdose › Indiana › Indianapolis
Opioid Overdose clinical trials in Indianapolis, IN
5 studies for Opioid Overdose are looking for participants at sites in and around Indianapolis (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Study of Brenipatide in Participants With Opioid Use Disorder
RecruitingPhase 2
- Indiana University Health Neuroscience Center, Indianapolis
Study to Assess the Use of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder
RecruitingPhase 1
- Indiana University School of Medicine, Indianapolis
Cerebral Physiology of NOWS
RecruitingHealthy volunteers welcome
- Indiana University - Riley Hospital for Children, Indianapolis
Better Options for Chronic Cancer Pain
RecruitingPhase 4Healthy volunteers welcome
- Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis
AvertD Post-Approval Study
RecruitingObservational studyHealthy volunteers welcome
- Concentrics Research, Indianapolis
About Opioid Overdose
Opioid overdose leads to slowing or stopping of breathing and sometimes death. You can take steps to help prevent an overdose, and respond to one with naloxone.
More about Opioid Overdose on MedlinePlus
Opioid Overdose trials in other cities
- Baltimore, MD18 studies
- New Haven, CT17 studies
- Philadelphia, PA15 studies
- New York City, NY12 studies
- Boston, MA12 studies
- Salt Lake City, UT7 studies
- Pittsburgh, PA7 studies
- Providence, RI6 studies
- San Francisco, CA6 studies
- Charleston, SC6 studies
- Birmingham, AL6 studies
- Ann Arbor, MI6 studies
Other studies in Indianapolis
- Non-Small Cell Lung Cancer32 studies
- Cancer (all types)25 studies
- Heart Failure23 studies
- Obesity20 studies
- Breast Cancer20 studies
- Metastatic Cancer19 studies
- Colorectal Cancer18 studies
- Ovarian Cancer17 studies
- Cardiovascular Disease16 studies
- Lung Cancer16 studies
- Endometrial Cancer15 studies
- Alzheimer's Disease14 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.